Tag: Biosimilar Drugs
FDA Approves Wezlana for Multiple Inflammatory Diseases
Approval of the biosimilar allows for interchangeable use with Stelara in both adult and pediatric patients
First Biosimilar Approved to Treat Multiple Sclerosis
Tyruko, biosimilar to Tysabri (natalizumab) injection, approved for treatment of clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
More Biosimilars Marketed in Germany, Switzerland Than U.S.
Monthly treatment costs of biosimilars were higher in the United States than corresponding costs in Germany, Switzerland
Biosimilars Could Cut Spending for Biologic Therapy in the U.S.
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment
